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AbstrACt
Objectives We sought to investigate the relationship 
between air quality and heart failure (HF) incidence and 
rehospitalisation to elucidate whether there is a threshold 
in this relationship and whether this relationship differs for 
HF incidence and rehospitalisation.
Methods This retrospective observational study was 
performed in an Australian state-wide setting, where 
air pollution is mainly associated with wood-burning for 
winter heating. Data included all 1246 patients with a 
first-ever HF hospitalisation and their 3011 subsequent all-
cause readmissions during 2009–2012. Daily particulate 
matter <2.5 µm (PM
2.5), temperature, relative humidity and 
influenza infection were recorded. Poisson regression was 
used, with adjustment for time trend, public and school 
holiday and day of week.
results Tasmania has excellent air quality (median 
PM
2.5=2.9 µg/m
3 (IQR: 1.8–6.0)). Greater HF incidences 
and readmissions occurred in winter than in other seasons 
(p<0.001). PM2.5 was detrimentally associated with HF 
incidence (risk ratio (RR)=1.29 (1.15–1.42)) and weakly so 
with readmission (RR=1.07 (1.02–1.17)), with 1 day time 
lag. In multivariable analyses, PM
2.5 significantly predicted 
HF incidence (RR=1.12 (1.01–1.24)) but not readmission 
(RR=0.96 (0.89–1.04)). HF incidence was similarly 
low when PM <4 µg/m3 and only started to rise when 
PM2.5≥4 µg/m
3. Stratified analyses showed that PM2.5 was 
associated with readmissions among patients not taking 
beta-blockers but not among those taking beta-blockers 
(p
interaction=0.011).
Conclusions PM2.5 predicted HF incidence, independent 
of other environmental factors. A possible threshold of 
PM2.5=4 µg/m
3 is far below the daily Australian national 
standard of 25 µg/m3. Our data suggest that beta-blockers 
might play a role in preventing adverse association 
between air pollution and patients with HF.
IntrOduCtIOn 
Heart failure (HF) is the leading cause of 
hospitalisation and rehospitalisation for adults 
aged over 65 years.1 2 Despite great improve-
ments in medical therapy and management 
of risk factors for HF, high readmission rates 
following an index HF admission continue 
to be a problem worldwide.3–5 In Australia, 
approximately 30 000 patients are diagnosed 
with HF each year, and the costs for HF read-
missions exceed $1 billion annually.6 Finding 
and eliminating the triggers of acute cardiac 
decompensation will reduce the social and 
economic burden of HF.
The phenomenon of seasonal varia-
tions in HF has been well established.7–9 
Although the underlying mechanisms are 
yet to be determined, observed increases 
in morbidity and mortality in cold weather 
may be partly due to increased ambient air 
pollution.10 11 A recent assessment of the 
global burden of disease ranked particulate 
matter air pollution as one of the leading 
causes of death and disability worldwide.12 
strengths and limitations of this study
 ► This observational study was performed in 
Tasmania, one of the world’s cleanest air areas with 
median PM2.5 level of 2.9 µg/m
3. This has given us 
an opportunity to investigate the association of air 
pollution with heart failure (HF) within a range of air 
quality that was much wider than that of other pre-
vious studies of its kind.
 ► Our analyses were based on a wide range of en-
vironmental factors to determine the independent 
association of air pollution with HF.
 ► The separation of HF incidence and readmission 
enabled us to investigate the differences in their as-
sociations with air pollution and other environmental 
factors.
 ► This study is limited by the absence of available data 
on personal exposure to active and passive smok-
ing, indoor temperature and other air pollutants.
 ► The adverse associations of air pollution on HF 
might have been underestimated in our study be-
cause our analyses were based on acute events 
associated with short-term exposures and did not 
take into account the effects of long-term exposure 
to air pollution.
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A recent systematic review and meta-analysis has shown 
an adverse relationship between increases in ambient 
particulate matter and HF hospitalisation and death.13 
However, it is unknown whether there is a threshold of 
particulate matter concentration in this relationship 
and whether this relationship may differ between HF 
incidence (defined as first-ever hospitalisation due to 
HF) and all-cause readmission.
Tasmania has excellent air quality in comparison 
with other parts of Australia. While having very low 
median level of fine particulate matter (PM2.5 <3 µg/m
3) 
compared with regions with considered good air quality 
like Colorado, USA (median PM2.5 7.7 µg/m
3)13 or bad 
air quality like Beijing (PM2.5 94±24 µg/m
3), there are 
days in Tasmania with high level of air pollution (PM2.5 
of up to 40 µg/m3).14 This very wide range of air quality 
provides a unique opportunity to investigate if there is a 
lower threshold for health outcomes associated with air 
pollution. The main cause of elevations in particulate 
matter in this setting is biomass smoke from wood heaters 
during winter and from bushfires and planned burns 
at other times of the year.15 In this retrospective cohort 
study, we measured air pollution and other environ-
mental factors including temperature, relative humidity 
and influenza epidemics and investigated the associa-
tions of these factors with HF incidence and readmission. 
Patients may be exposed to different lifestyles, treatments 
and medications before and after the diagnosis of HF. By 
being able to separate HF incidence and readmission, we 
sought to determine the presence and mechanism of any 
differences in the relationship of these outcomes with 
environmental factors.
MethOds
study population
This retrospective cohort study included all 1246 patients 
(median age 78 years, 51% male) who had their first-ever 
admission to a public hospital in Hobart and Launceston 
(Tasmania, Australia) due to HF between July 2009 and 
July 2012. These patients were identified by their coded 
diagnoses (International Classification of Diseases, Ninth 
Revision, Clinical Modification 402.x1, 404.x1, 404.x3, 
428.x and  428. xx).
Primary outcomes
The primary outcomes of this study were daily count of 
HF incidence (defined as first hospitalisation due to HF) 
and subsequent all-cause readmissions that followed the 
index admission during the study period. Dates of hospi-
talisation were obtained from administrative data from 
the Clinical Informatics and Business Intelligence Unit 
of the Department of Health and Human Services of 
Tasmania.
Patient and public involvement
Patients or public were not involved in this study.
environmental data
The Australian state of Tasmania is an island to the 
south of the continent, characterised by a colder and 
wetter climate, and cleaner air quality, than the rest of 
the Australia. In this southern hemisphere, winter is 
defined as June–August, spring as September–November, 
summer as December–February and autumn as March to 
May.16 Hobart (population 247 461 in 2011) and Laun-
ceston (population 137 561 in 2011) are the two largest 
cities of Tasmania (total population 495 354 in 2011) and 
provide residence for nearly 80% of the whole state’s 
population.17 There is only one public hospital in each of 
Hobart (the Royal Hobart Hospital) and Launceston (the 
Launceston General Hospital). Air pollution in Hobart 
and Launceston was estimated by hourly concentrations 
of particulate matter less than 2.5 µm in diameter (PM2.5) 
with gravimetric sampling methods.18 Simultaneous moni-
toring of air quality was previously conducted at multiple 
sites and showed highly correlated measurements.18 
After these findings, a representative site was selected for 
ongoing monitoring air quality in each city all year. Data 
on daily temperature and relative humidity were from the 
Bureau of Meteorology.19 Daily count of positive labora-
tory tests for influenza in Tasmania was also recorded.
demographic and clinical data
Additional demographic and clinical data were collected 
from medical records of the first HF admission.20
statistical analyses
Cumulative incidence of HF was estimated by taking the 
ratio of new HF cases to the total population of Hobart 
and Launceston. We calculated daily concentration of 
PM2.5 by averaging their hourly measurements from each 
day, for Hobart and Launceston separately. Daily mean 
temperature and relative humidity were calculated by 
averaging maximum and minimum temperature and 
relative humidity of each day. These measurements were 
then weighted based on the ratio of population in the 
two cities to derive an average value to be used in anal-
ysis. The rolling sum of positive influenza tests during the 
last 7 days (including the current day) was calculated, and 
the 90th percentile cut-off was used to define influenza 
epidemic. Pearson correlation was used to estimate the 
strength of the relationships among these environmental 
factors. Because of the nature of our primary outcomes 
(count variables), Poisson regression was used to estimate 
the associations of air pollution and other environmental 
factors with the primary outcomes of this study. These 
associations were estimated for the same day (lag0) and 
up to 5 days before the outcome (lag1 to lag5) and for the 
previous 3 days moving average (lag1–3). Binary variables 
were created for weekday and weekend, school holidays 
and public holidays for adjustment. A smooth function of 
calendar time (natural cubic splines) with 7 df per year 
was used to adjust for seasonal patterns and any other 
time-dependent influences on HF admissions (including 
long-term trends due to changes in medical practice). 
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Because the relationship of temperature with HF admis-
sions appeared to be linear in our study (as shown in 
Results section, possibly due to the cool climate nature 
of Tasmania), we fitted a linear term for temperature in 
our analysis.
results
heart failure
Data on HF hospitalisations are shown in table 1.
Patients from Hobart and Launceston had very similar 
socioeconomic status (Index of Relative Socioeconomic 
Advantage and Disadvantage: 912±105 vs 914±90, p=0.73). 
Only a small proportion of patients from both cities were 
from remote/very remote areas (Hobart: 2% and Laun-
ceston: 1%).
There were 1246 HF incidences (median: 1 new case/
day). The estimated cumulative incidence of HF was 3.2 
per 1000 persons over the study period. After the first 
HF hospitalisation, there were 3011 subsequent all-cause 
readmissions (with 35% being HF-specific readmissions) 
during the study period. The majority of patients (70%) 
were classified as New York Heart Association (NYHA) 
class II/III. Diuretics were the most commonly used 
medication, followed by ACE inhibitors (ACEis) or angio-
tensin receptor blockers (ARBs).
environmental factors
The distribution of PM2.5 is shown in figure 1.
Median levels of PM2.5, temperature and relative 
humidity are shown in table 1. The correlations among 
these measurements, which are moderate at best, are 
shown in table 2.
seasonal variations of hF
The seasonal variations of HF are illustrated in figure 2. 
The incidence of new cases of HF peaked during winter 
months (June–August). This phenomenon also aligned 
well with the peaks in PM2.5 and relative humidity and with 
the lowest levels of temperature. Figure 3 further demon-
strated this seasonal variation in HF by showing signifi-
cant trends in HF incidence and readmissions that both 
peaked during winter and reduced during other seasons.
Associations with primary outcomes
Table 3 shows univariable associations of air pollution 
and other environmental factors with HF incidence and 
all-cause readmission.
While air pollution was adversely associated with HF 
incidence, it was not or very weakly associated with read-
mission. Temperature, relative humidity and influenza 
epidemic periods, however, were associated with both 
HF incidence and all-cause readmission. These findings 
were consistent with those of HF-specific readmissions 
(online supplementary table 1). It is consistent for all 
Table 1 Data on heart failure incidence and readmission, 
and environmental factors in Hobart and Launceston 
(Australia) in 2009–2012 (1096 days)
Heart failure hospitalisations
Incidence (counts/day) 1 (0–2)
All-cause readmission (counts/day) 3 (2–4)
Male 632 (51)
Age at index admission (years) 80 (72–86)
NYHA classification before discharge
  Class I 174 (14)
  Class II 449 (36)
  Class III 424 (34)
  Class IV 199 (16)
Beta-blocker use 660 (53)
ACEi/ARB use 909 (73)
Diuretic use 1159 (93)
Aldosterone use 386 (27)
Digoxin use 274 (22)
Antiarrhythmic medication use 100 (8)
Environmental factors
Daily air concentration of PM2.5 (µg/m
3) 2.9 (1.8–6.1)
Mean daily temperature (°C) 13.2 (9.9–16.7)
Min daily temperature (°C) 8.2 (4.9–11.7)
Max daily temperature (°C) 18.0 (14.6–22.2)
Daily relative humidity (%) 74 (66–82)
Data are reported as median (IQR) or n (%).
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; NYHA, 
New York Heart Association.
Figure 1 Distribution of PM2.5.
Table 2 Correlations among the environmental factors
PM2.5 Temperature
Relative 
humidity
PM2.5 1.00
Temperature −0.38* 1.00
Humidity 0.35* −0.23* 1.00
*P<0.001.
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environmental factors (PM2.5, temperature and relative 
humidity) that their associations with HF incidence were 
either strongest or second strongest with three lagging 
days average. This suggests that the environmental effect 
on HF is through continuous exposure, and for consis-
tency, this three lagging day average (lag1–3) variables 
will be used for multivariable analysis. The associations 
between environmental factors and HF are also illus-
trated in figures 4–6, demonstrating dose–response 
relationships.
Table 4 shows multivariable associations of air pollution 
and other environmental factors with the outcomes.
Among the environmental factors, only PM2.5 and 
temperature remained as significant predictors of HF 
incidence. However, while temperature, relative humidity 
and presence of influenza epidemic were significantly 
associated with readmissions, PM2.5 did not predict read-
missions among HF patients.
Possible threshold of PM2.5 in predicting hF incidence
The relationship of PM2.5 with HF incidence count per 
day is shown in figure 4. Although there was a highly 
significant trend of increasing HF incidence throughout 
the whole range of PM2.5 included in this study, the level 
of HF incidence count per day appeared to increase when 
PM2.5 reached the fourth quintile. This finding suggests 
that there might be a threshold in the relationship of 
PM2.5 with HF incidence. Therefore, we further investi-
gated this relationship by breaking the whole range of 
PM2.5 into nine groups each of which contained approx-
imately 100 days of our study period (figure 7). The 
HF incidence count per day started to rise when PM2.5 
was beyond 4 µm/m3. While the relationship between 
PM2.5 and HF incidence was null when PM2.5 <4 µm/m
3 
(RR=0.99 (95% CI 0.92 to 1.07)), it was significantly 
positive when PM2.5 ≥4 µm/m
3 (RR=1.20 (95% CI 1.07 to 
1.34)). This was consistent with no correlation between 
PM2.5 and HF incidence when PM2.5 <4 µm/m
3 (β=−0.01 
(−0.07 to 0.05), p=0.48) and a positive correlation when 
PM2.5 ≥4 µm/m
3 (β=0.17 (0.07 to 0.35), p=0.008). These 
findings are controlled for temperature. Consistent find-
ings were found when the PM2.5 range was broken by 
deciles (online supplementary figure 1). HF incidence 
count per day started to rise when PM2.5 was beyond the 
seventh decile (median 4.1 µm/m3). Using any threshold 
greater than 4 µm/m3 would result in a positive associa-
tion between PM2.5 and HF incidence when PM2.5 below 
the new threshold (not shown).
Possible protective effects of hF medication against air 
pollution
The concentration of PM2.5 was adversely associated with 
HF incidence but not with readmission. We further inves-
tigated whether HF medications prescribed after the 
confirmed diagnosis of HF may play a role in protecting 
patients against the adverse association with air pollution. 
We classified patients by whether they were prescribed 
common HF medications (beta-blockers, ACEi/ARB and 
diuretics) after their first admission with HF. For ACEi/
ARB and diuretics, there was no difference in the asso-
ciation of PM2.5 with readmission count per day among 
patients who took these medications (ACEi/ARB: β=0.04 
(−0.02 to 0.08), p=0.15, diuretics: β=0.05 (−0.01 to 0.11), 
p=0.084) and those who did not (ACEi/ARB: β=0.02 
(−0.01 to 0.03), p=0.27, diuretics: β=0.04 (−0.02 to 0.09), 
p=0.11). However, while PM2.5 was not associated with 
readmission count per day among patients who took beta-
blockers (figure 8, β=−0.01 (−0.07 to 0.06), p=0.89), PM2.5 
was positively associated with readmission count per day 
among patients who did not take beta-blockers (figure 8, 
β=0.14 (0.05 to 0.23), p=0.002). There was a signifi-
cant interaction between beta-blockers use and PM2.5 in 
their association with HF readmission (p=0.011). When 
restricting the analysis to HF-specific readmissions only, 
the association of PM2.5 with readmission count per day 
was also stronger among patients who did not take beta-
blockers (β=0.09 (0.01 to 0.19), p=0.01) than that among 
patients who took beta-blockers (β=0.03 (−0.02 to 0.07), 
p=0.34).
Figure 2 Seasonal variations of heart failure and 
environmental factors.
Figure 3 Heart failure incidence and readmission by 
seasons.
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dIsCussIOn
This study investigated the relationships of particulate 
air pollution and other environmental factors with HF 
incidence and all-cause readmission and provided several 
important and novel findings. Acute exposure to ambient 
particulate matter is adversely associated with increased 
HF incidence after adjusting for other environmental 
factors, even in regions with very low air pollution such 
Table 3 Univariable Poisson regression of environmental factors with heart failure incidence and readmissions
Heart failure incidence All-cause readmissions
Risk ratio P values Risk ratio P values
PM2.5 (per 10 µg/m
3)
  Lag0 day 1.18 (1.08 to 1.32) <0.001 1.01 (0.94 to 1.09) 0.75
  Lag1 day 1.29 (1.15 to 1.42) <0.001 1.07 (1.00 to 1.14) 0.06
  Lag2 day 1.24 (1.12 to 1.38) <0.001 1.03 (0.96 to 1.10) 0.47
  Lag3 day 1.13 (1.01 to 1.26) 0.005 0.98 (0.91 to 1.05) 0.58
  Lag4 day 1.16 (1.03 to 1.29) 0.013 1.01 (0.94 to 1.08) 0.85
  Lag5 day 1.17 (1.07 to 1.29) 0.001 1.01 (0.94 to 1.09) 0.70
  Lag1-3 day average 1.27 (1.14 to 1.44) <0.001 1.02 (0.94 to 1.10) 0.67
Temperature (per 10°C)
  Lag0 day 0.63 (0.56 to 0.70) <0.001 0.83 (0.76 to 0.90) <0.001
  Lag1 day 0.67 (0.58 to 0.76) <0.001 0.84 (0.77 to 0.91) <0.001
  Lag2 day 0.64 (0.57 to 0.72) <0.001 0.81 (0.75 to 0.88) <0.001
  Lag3 day 0.64 (0.56 to 0.73) <0.001 0.82 (0.75 to 0.89) <0.001
  Lag4 day 0.60 (0.52 to 0.68) <0.001 0.80 (0.74 to 0.87) <0.001
  Lag5 day 0.64 (0.56 to 0.73) <0.001 0.84 (0.77 to 0.91) <0.001
  Lag1–3 day average 0.62 (0.54 to 0.71) <0.001 0.81 (0.74 to 0.88) <0.001
Relative humidity (per 10%)
  Lag0 day 1.02 (0.97 to 1.07) 0.49 1.11 (1.07 to 1.14) <0.001
  Lag1 day 1.01 (0.96 to 1.06) 0.69 1.09 (1.06, 1.13) <0.001
  Lag2 day 1.03 (0.98 to 1.09) 0.09 1.10 (1.07 to 1.14) <0.001
  Lag3 day 1.07 (1.02 to 1.12) 0.005 1.14 (1.10 to 1.18) <0.001
  Lag4 day 1.04 (0.99 to 1.08) 0.17 1.09 (1.06 to 1.13) <0.001
  Lag5 day 1.04 (1.00 to 1.09) 0.05 1.10 (1.07 to 1.13) <0.001
  Lag1–3 day average 1.06 (1.01 to 1.13) 0.064 1.17 (1.13 to 1.22) <0.001
Influenza epidemic (yes vs no) 1.12 (1.02 to 1.24) 0.014 1.14 (1.01 to 1.29) 0.003
Figure 4 Associations of quintile of PM2.5 with heart failure 
incidence and readmission.
Figure 5 Associations of temperature with heart failure 
incidence and readmission.
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as Tasmania. More importantly, the relationship between 
PM2.5 and HF incidence appeared to have a threshold 
of approximately 4 µg/m3, which is far below the daily 
Australian and WHO standard of PM2.5 of 25 µg/m
3. 
While temperature and relative humidity were associated 
with readmission, air pollution was very weakly associated 
with all-cause readmission among patients with HF. This 
might be partly due to protective effects of beta-blockers.
Air pollution and hF
Although the mechanisms underlying the relation-
ship between particulate air pollution and HF are not 
well understood, possible causal pathways through 
increased oxidative stress and inflammation have been 
proposed.21–23 These pathways involve adverse effects on 
both the systemic arterial and venous circulation and lead 
to an increase in systemic blood pressure, myocardial isch-
aemia, vasoconstriction, atherosclerosis and arrhythmia. 
All these factors contribute to the exacerbation of HF. 
The positive association of air pollution with HF inci-
dence shown in our study suggests that air pollution also 
plays a role in the development of HF.
To the best of our knowledge, this is the first time a 
threshold of PM2.5 has been detected for its association 
with HF. The very low threshold of PM2.5 observed in our 
study (approximately 4 µg/m3) explains the persistent 
adverse effects of air pollution when PM2.5 levels were 
lower than the Australian and WHO standard of 25 µg/
m3.24 25 This is even lower than the target concentration 
of 5.8 µg/m3 used in the recent meta-analysis,13 which 
was the lowest concentration observed in 116 cities in the 
USA during 1999–2000 PM2.5 collection period.
26 27 The 
finding that PM2.5 was linearly associated with HF when 
beyond the threshold is consistent with that found in 
other studies13 and suggests that any effort to improve air 
quality is beneficial if a level of PM2.5 as low as 4 µg/m
3 is 
too difficult to achieve. Our findings link well to those 
in previous studies and together they form a complete 
picture of the relationship between PM2.5 and HF.
Possible protective effects of beta-blockers
PM2.5 was associated with increased HF incidence after 
accounting for other environmental factors but was not 
associated with HF specific or all-cause readmission. 
Although there were no interactions of ACEi/ARB or 
diuretic use on the relationship between PM2.5 level and 
HF readmission, there was a significant interaction of 
beta-blocker use with this relationship. This difference 
in the relationship of PM2.5 with HF incidence and HF 
specific or all-cause readmission may be partly due to the 
protective effects of beta-blockers. Because the mecha-
nisms underlying the association between PM2.5 and HF 
are not fully understood, how the use of beta-blockers 
may contribute to this relationship is further unclear. 
However, there are three possible mechanisms: (1) beta-
blockers are known to influence the autonomic nervous 
Figure 6 Associations of relative humidity with heart failure 
incidence and readmission.
Table 4 Multivariable Poisson regression of environmental factors with heart failure incidence and readmissions
Heart failure incidence All-cause readmissions
Risk ratio P values Risk ratio P values
PM2.5 lag1–3 day (per 10 µg/m
3) 1.10 (1.01–1.22) 0.039 0.96 (0.89–1.04) 0.44
Temperature lag1–3 day (per 10°C) 0.69 (0.59–0.81) <0.001 0.88 (0.78–0.96) 0.009
Relative humidity lag1–3 day (per 10%) 0.98 (0.92–1.05) 0.56 1.10 (1.05–1.15) 0.001
Influenza epidemic (yes vs no) 1.01 (0.80–1.21) 0.45 1.20 (1.06–1.38) 0.005
Further adjusted for weekday and weekend, school and public holiday and time trend.
Figure 7 Possible threshold of PM2.5 with heart failure (HF) 
incidence.
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system, which is one of the proposed causal pathways 
between PM2.5 and HF. Specifically, previous studies have 
shown that the use of beta-blockers modifies the effect 
of PM2.5 on heart rate variability
28–30—a reliable marker 
of autonomic activity and a predictor of increased risk 
for cardiovascular morbidity and mortality.31 32 (2) It is 
also reported that beta-blockers provide anti-inflamma-
tory benefits in chronic HF by lowering the circulating 
level of tumour necrosis factor-alpha and increasing the 
levels of anti-inflammatory cytokines.33 (3) Furthermore, 
a protective effect of beta-blockers on exercise-induced 
ST depression after exposure to PM2.5 was also reported.
34
One could argue that the patients without beta-blocker 
could not have tolerated taking them because they were 
too sick. Indeed, patients who were prescribed beta-
blockers in our study were at younger age at their first 
admission and had slightly lower mean NYHA class, 
Charlson comorbidity index, heart rate and respiratory 
rate (online supplementary table 2), but there was no 
association with socioeconomic factors. However, patients 
who were prescribed ACEi/ARB also had similar charac-
teristics (online supplementary table 3). Therefore, the 
protective effects of beta-blockers use (but not of ACEi/
ARB) that were observed in our study were likely not 
fully explained by these discrepancies. However, because 
patients with HF usually have respiratory comorbidities 
such as asthma or chronic obstructive pulmonary disease 
that may contraindicate the use of beta-blockers, we 
could not completely exclude the possibility of a residual 
confounding caused by these conditions in our study. 
Thus, further studies on this are needed.
differences between hF incidence and readmission
Apart from the differences in the associations with air 
pollution, HF incidence and readmission were also 
different in their associations with relative humidity and 
influenza infection epidemic. While these environmental 
factors were not independently associated with HF inci-
dence, they were independently and adversely associ-
ated with readmission. This may be due to increased 
vulnerability once patients have developed HF, and a 
mild trigger might also lead to exacerbation of HF, or 
this may be due to the attenuation of significant effect 
of particulate air pollution resulted from beta-blocker 
use. The consistent findings for HF-specific readmis-
sions and all-cause readmissions in our study support this 
speculation.
strengths and limitations
This study has some particular strengths. The PM2.5 
median level of 2.9 µg/m3 is a unique aspect of the study, 
as Tasmania has some of the world’s cleanest air. This has 
given us an opportunity to investigate the association of 
air pollution with HF within a range of air quality that 
was much wider than that of other previous studies of its 
kind. Second, our analyses were based on a wide range of 
environmental factors to determine the association of air 
pollution with HF. Third, the separation of HF incidence 
and readmission enabled us to investigate the differences 
in their associations with air pollution and other environ-
mental factors.
This study is limited by the absence of available data on 
personal exposure to active and passive smoking, indoor 
temperature and other air pollutants (such as nitrogen 
dioxide, ozone and sulfur dioxide). Second, the adverse 
association between air pollution and HF might have 
been underestimated in our study, because our analyses 
were based on acute events associated with short-term 
exposures and did not take into account the effects of 
long-term exposure to air pollution. Third, our study did 
not take into account the duration, dosage and adher-
ence of beta-blocker use and factors (including severity 
of HF) that may influence the use of beta-blockers. 
Future studies are therefore required to confirm this 
relationship and further explore if the benefit of beta-
blockers use in this context is dose–response. Because 
most HF patients with reduced ejection fraction would 
have been prescribed beta-blockers if not contraindi-
cated, it is important to confirm our findings for HF 
patients with preserved ejection fraction. Finally, due to 
the retrospective nature of our study, we only had echo-
cardiography data on a subset of 451 patients (online 
supplementary tables 2 and 3) and were unable to inves-
tigate this matter. Further studies are therefore needed 
for this investigation.
COnClusIOns
In summary, our findings confirm the seasonal varia-
tions of HF and demonstrate an adverse relationship of 
air pollution with HF even in a very low range of PM2.5. 
For the first time, a possible threshold of PM2.5=4 µg/
m3 has been detected in our study. This finding should 
encourage us to keep improving the air quality to reduce 
the burden of HF. Further studies are required to confirm 
the possible protective effects of beta-blockers against air 
pollution.
Figure 8 Possible protective effects of beta-blockers.
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